Laekna Therapeutics is a clinical-stage biotech specializing in oncology and immunology, with a pipeline focused on drug-resistant cancers and combination-therapy strategies. Founded in 2016 and headquartered in Shanghai, with operations in New Jersey, the company develops small molecules and biologics targeting critical signaling pathways implicated in tumor growth, immune evasion, and therapy resistance.
In recent years, Laekna has accelerated its global clinical program, advancing multiple assets into Phase I and Phase II studies for metastatic breast, ovarian, and prostate cancers. Its combination-therapy strategy, centered on modulation of the PI3K/AKT and endocrine resistance pathways, reflects a broader industry shift toward biomarker-guided oncology treatments.
Laekna is strengthening its oncology portfolio through the continued advancement of LAE002 (afuresertib), a pan-AKT inhibitor now being evaluated in global Phase Ib/III studies in combination with fulvestrant for HR-positive, HER2-negative metastatic breast cancer. This approach targets endocrine-therapy resistance, a key clinical challenge, and aligns with broader industry momentum toward biomarker-guided combination regimens.
Taken together, these advances position Laekna as an increasingly relevant precision-oncology company, with a pipeline that directly targets the mechanisms driving therapy resistance in metastatic cancers. By prioritizing pathway-directed combination regimens and biomarker-guided strategies, Laekna aligns itself with where oncology drug development is moving, strengthening its potential competitiveness as the field shifts toward more individualized and mechanistically informed treatments.
Funding profile and market positioning
Laekna strengthened its financial position ahead of its IPO through a US$61 million Series D financing round announced in 2022. The round was led by CS Capital, with participation from Worldstar, Infinity Capital, and other institutional investors. Across four financing rounds, Laekna has been backed by major healthcare investors. Before the Series D, SCGC led the US$61 million Series C in October 2020, while GP Healthcare Capital and OrbiMed Healthcare Fund Management led the Series B and Series A rounds. According to the company, the proceeds were allocated to accelerate development of its core oncology programs, including the pan-AKT inhibitor afuresertib (LAE002) and the CYP17A1/17,20-lyase inhibitor LAE001, both of which are being evaluated in global clinical studies for drug-resistant breast and prostate cancers. The Series D raise reinforced investor confidence in Laekna’s combination-therapy strategy and provided additional runway to advance multiple mid-stage clinical trials.
Laekna also completed one of 2023’s largest biotech IPOs on the Hong Kong Stock Exchange, raising approximately HK$791 million (about US$101 million) to support the expansion of its programs in oncology and liver-disease. According to deal coverage, the offering strengthened the company’s ability to advance its clinical pipeline and pursue broader development initiatives across its targeted therapeutic areas. BioWorld also noted that the IPO proceeds position Laekna to accelerate ongoing trials and deepen its focus on diseases driven by complex signaling and resistance mechanisms.
Furthermore, Laekna strengthened its market position by securing a collaboration in which Eli Lilly will fund and conduct the Phase I study of LAE102. This structure provides non-dilutive support that helps preserve Laekna’s post-IPO capital and extend its development runway. The partnership also signals external validation of Laekna’s biologics discovery capabilities and increases the company’s visibility in the competitive obesity and metabolic disease market.
Laekna’s 2025 corporate update indicates a broader strategic shift toward diversification, supported by a growing clinical footprint and sustained post-IPO capital deployment. With seven active clinical trials spanning oncology and metabolic disease, the company is allocating resources across multiple therapeutic areas to reduce development risk and expand potential revenue pathways.
These financing milestones, partnerships, and pipeline expansions illustrate how Laekna has built a stronger and more diversified market position since 2022. The combination of institutional backing, a sizeable HKEX IPO, non-dilutive support from Eli Lilly, and a growing portfolio of seven active clinical trials provides the company with both capital stability and strategic breadth. This positions Laekna to advance multiple high-value programs in parallel, reduce development risk, and compete across established oncology markets as well as emerging areas like obesity and muscle preservation, strengthening its prospects for long-term growth in a competitive biotech landscape.
Laekna Therapeutics: Patenting Activity
Laekna’s patenting activity shows a clear expansion in research output beginning in 2019, when the company recorded thirteen patents. Activity accelerated sharply in 2021, with 27 new filings, followed by additional submissions in 2022 and 2023.
Although the dataset reflects a relatively young portfolio with few granted patents at this stage, the steady rise in pending applications indicates sustained investment in new drug modalities, combination-therapy concepts, and platform technologies. This pattern aligns with Laekna’s transition from early discovery into broader clinical development, suggesting that the company is building a foundational IP estate to support global commercialization efforts over the coming decade.
Laekna Therapeutics: Top Jurisdictions
Laekna’s patent portfolio spans several major jurisdictions, with the European Patent Office accounting for the largest share at twenty pending applications, followed by Hong Kong, China, the United States, Japan, and select emerging markets. It is noteworthy that all of Laekna’s patents originate as WO (PCT) filings, indicating a deliberate strategy to secure early global protection and maintain maximum flexibility before entering country-specific phases.
Although the company was founded in China, its strongest concentration of pending applications in the EPO suggests a strategic focus on high-value pharmaceutical markets and potential European commercialization opportunities. This WO-first approach, combined with a geographically diverse set of pending national applications, reflects a forward-looking IP strategy designed to preserve global optionality while its clinical programs continue to advance.
Laekna Therapeutics: Top Legal Representatives
Laekna’s patent filings are handled primarily by a small group of specialized intellectual property firms. AFD China Intellectual Property Law Office leads with ten filings, indicating its central role in managing the company’s global PCT strategy. CCPIT Patent and Trademark Law Office follows with five filings, while Global Zen IP Services Limited supports an additional four.
This concentration of work among experienced China-based and international IP firms suggests a coordinated approach to securing early global protection and navigating multi-jurisdictional patent pathways as Laekna’s portfolio expands.
Laekna Therapeutics: Top Technology Areas
Laekna’s patent portfolio is concentrated in therapeutic applications and drug compositions, with A61P and A61K forming the core of its technological focus. This reflects a pipeline centered on developing medicines for specific disease indications and optimizing their formulation for clinical use. The strong presence of C07K highlights active work in peptides and antibody-based therapies, consistent with the company’s expansion into biologics.
Activity in C12N indicates supporting biotechnology methods, such as cell-based or molecular techniques used in drug discovery and validation. Meanwhile, C07D captures Laekna’s development of heterocyclic small molecules, which underpins its targeted oncology programs. Together, these categories show a balanced investment in both small-molecule and biologic modalities, supported by foundational biotechnological tools.
Laekna’s emerging portfolio in oncology, fibrosis, and metabolic innovation
Laekna’s recent patent filings highlight a broad scientific scope that spans metabolic disease, liver health, and targeted oncology. The company is advancing antibody-based therapies aimed at improving muscle and metabolic function, exploring direct interventions to reduce liver scarring by eliminating fibrosis-driving cells, and developing small-molecule inhibitors that disrupt key cancer growth pathways. Together, these inventions illustrate Laekna’s effort to build a diversified portfolio of next-generation therapeutics grounded in pathway-specific and mechanism-driven innovation.
Blocking ACVR2A to support muscle and metabolic health
Researchers are increasingly looking beyond appetite control to address the biological factors that influence muscle strength and metabolic health. One of these factors is ACVR2A, a receptor involved in pathways that regulate muscle growth and tissue balance. When ACVR2A becomes overactive, it can contribute to muscle loss and other metabolic problems. Laekna’s scientists explored whether blocking this receptor could help counteract these harmful effects.
The European patent EP4395822, describes antibodies that bind to and inhibit ACVR2A. By blocking this receptor, the antibodies are designed to prevent biological signals that lead to muscle decline or metabolic dysfunction. According to the filing, these antibody-based treatments could be applied in diseases linked to excessive ACVR2A activity, offering a potential approach to preserving muscle and improving metabolic balance.
The patent was published on July 10, 2024 and lists inventors Lu Chris Xiangyang (CEO), Gu Xiang-Ju Justin (Executive Director Chief Scientific Officer), Zhang Ruipeng, Yang Mengxue, Zhang Minhua, and Hu Meijuan. The application is represented by Dehns, a well-known European intellectual property law firm.
Targeting the cells that drive liver scarring
Liver fibrosis is a condition in which the liver becomes scarred over time due to chronic injury, such as hepatitis, fatty liver disease, or long-term alcohol use. As scar tissue builds up, the liver gradually loses its ability to function normally. A major driver of this process is the overactivation of hepatic stellate cells (HSCs), which produce the fibrous material that forms these scars.
The patent WOCN2021/104201, published in Hong Kong as HK40114909, describes an approach for the selective depletion of activated hepatic stellate cells. According to the application, the invention provides methods and compositions designed to reduce the activity and number of these harmful cells, aiming to slow or potentially reverse fibrosis by targeting its cellular source. By focusing on the primary drivers of scar formation, the invention outlines a more direct, disease-modifying strategy for improving liver health.
Filed on July 2, 2021 and published on March 21, 2025, the patent lists inventors Lu Chris Xiangyang (CEO), Gu Xiang-Ju Justin (Executive Director Chief Scientific Officer), Zhang Ruipeng, and Zhang Minhua. The application is represented by Global Zen IP Services Limited, which manages the filing in the Hong Kong jurisdiction.
Developing PI3Kα inhibitors to disrupt cancer growth signals
Many cancers rely on overactive signaling through the PI3Kα pathway, which controls cell growth, survival, and metabolism. When this pathway becomes dysregulated, tumors can grow more aggressively and resist standard therapies. Drugs that inhibit PI3Kα aim to shut down these signals, making the pathway a major focus of modern targeted cancer treatment.
The patents WOCN2023/113301 and WOCN2023/140658, published internationally as WO2025/036439 and later in Europe, describe a series of multicyclic small-molecule compounds designed to function as PI3Kα inhibitors. According to the application, these compounds and their related pharmaceutical formulations can be used to block PI3Kα activity and may be applied in the treatment of cancers and other diseases driven by this signaling pathway. By introducing new chemical scaffolds for PI3Kα inhibition, the invention contributes to ongoing efforts to develop more precise and potentially more effective targeted therapies.
Filed on August 16, 2023 and published on February 20, 2025, the patent lists inventors Li Ming, Zhang Ruipeng, Chen Chun-Yen, and Gu Xiang-Ju Justin (Executive Director Chief Scientific Officer). The application is represented by AFD China Intellectual Property Law Office, which manages the filing across the WO and European jurisdictions.
Strategic Implications
Laekna’s expanding patent estate, advancing clinical programs, and strengthened financial base demonstrate a corporate innovation strategy aimed at long-term growth across multiple therapeutic frontiers. By investing in both small-molecule and antibody platforms, extending its reach beyond oncology into metabolic disease and fibrosis, and securing the capital and partnerships needed to scale these programs, the company is positioning itself as a diversified biotech competitor with increasing global relevance. As its WO-origin patents move toward national protection and its clinical data matures, Laekna’s ability to convert scientific breadth into commercial opportunity will likely define its trajectory in the next decade.
